A Phase 1, Open-label Study to Investigate the Pharmacokinetics of Tralokinumab (CAT-354) in Adolescents With Asthma

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

January 31, 2013

Study Completion Date

January 31, 2013

Conditions

Asthma

Interventions

BIOLOGICAL

Tralokinumab 300 mg

Participants aged 12 to 14 years and 15 to 17 years will receive a single dose of tralokinumab (CAT-354) 300 mg, subcutaneously on Day 1.

Trial Locations (3)

Research Site, Gliwice

Research Site, Karpacz

Research Site, Lodz